Goldman Sachs Group set a €111.00 ($129.07) target price on Bayer (FRA:BAYN) in a research note released on Wednesday, October 17th. The brokerage currently has a buy rating on the healthcare company’s stock.
A number of other brokerages have also commented on BAYN. Independent Research set a €105.00 ($122.09) price objective on shares of Bayer and gave the stock a neutral rating in a report on Monday, July 16th. Kepler Capital Markets set a €84.00 ($97.67) price objective on shares of Bayer and gave the stock a buy rating in a report on Monday, September 24th. Citigroup set a €93.00 ($108.14) price objective on shares of Bayer and gave the stock a neutral rating in a report on Tuesday, August 28th. HSBC set a €82.00 ($95.35) price objective on shares of Bayer and gave the stock a neutral rating in a report on Thursday, September 13th. Finally, Barclays set a €100.00 ($116.28) target price on shares of Bayer and gave the company a neutral rating in a research note on Thursday, July 12th. Seven equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of €96.88 ($112.65).
Bayer stock traded up €0.28 ($0.33) during trading on Wednesday, reaching €71.00 ($82.56). 2,505,231 shares of the company’s stock were exchanged. Bayer has a 52-week low of €91.58 ($106.49) and a 52-week high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Further Reading: Cash Flow
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.